MACROGENICS, INC. (NASDAQ:MGNX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On November 16, 2017, MacroGenics, Inc. (the “Company”) filed a Current Report on Form 8-K to report that the Board of Directors of the Company (the “Board”) appointed Jay Siegel, M.D. to the Company’s Board effective November 13, 2017 (the “Original Filing”). At the time, the Board had not made a determination regarding any Board committee assignments for Dr. Siegel. The Company is filing this Current Report on Form 8-K/A to report that on February 23, 2018, the Board appointed Dr. Siegel to the Compensation Committee of the Board effective on that date. Other than the preceding disclosure, no other disclosure reported in the Original Filing is amended in this Current Report.

About MACROGENICS, INC. (NASDAQ:MGNX)
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment. It develops therapeutic product candidates using its antibody-based technology platforms and in partnership with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily against various cancers. Its product candidates include margetuximab, enoblituzumab, MGD006, MGD007, MGD011, MGD009, MGD013, MGD010, teplizumab and MGD014. Its clinical product candidate, margetuximab, is a monoclonal antibody directed against human epidermal growth factor receptor 2, (HER2), including certain types of breast and gastroesophageal cancers.